BIOSCIENCE RESEARCH HIV testing
Upcoming SlideShare
Loading in...5
×
 

BIOSCIENCE RESEARCH HIV testing

on

  • 279 views

Research project, Biosciences, Life Sciences Research and Development, Biotechnology Shelter, Outsourcing R & D.

Research project, Biosciences, Life Sciences Research and Development, Biotechnology Shelter, Outsourcing R & D.

Statistics

Views

Total Views
279
Views on SlideShare
279
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Less than 1% of the urban population of Africa had been tested for HIV Tijuana Hospital General send their samples for testing to Mexico city (more than 1700 miles)Need more effective ways to test for HIV
  • WHO estimated that, as of 2000, inadequate blood screening had resulted in 1 million new HIV infections worldwide
  • Rapid, flexible, simple, accurate, looking for antibodies
  • Comisión Federal para la Protección contra RiesgosSanitarios.
  • Ethical Review Board Approval of protocolRevision de protocoloEl Centro Ambulatoriopara la Prevención y Atención en SIDA e Infecciones de Transmisión Sexual (CAPASITS)
  • El Centro Ambulatoriopara la Prevención y Atención en SIDA e Infecciones de Transmisión Sexual (CAPASITS)
  • ROUTINE COSTS IN CLINICAL TRIAL, COVERAGE, HEALTHCARE, DIGITAL, RECRUITMENTS, ASSISTEN PROJECT COORDINATOR, ASSISTANT SCIENTIST, MULTI-MODAL OUTREACH, HIGHER ENGAGED MEMBERS OF THE PROJECT. PROVIDE A MINI - TABLET.
  • Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.

BIOSCIENCE RESEARCH HIV testing BIOSCIENCE RESEARCH HIV testing Presentation Transcript

  • Evaluation of accuracy of rapid point-of-care HIV test with oral fluid versus the conventional blood by fingerstick test Marco Velazco Rivera Octavio Romo Fewell 1
  • HIV Statistics • Human immunodeficiency virus (HIV) is a lentivirus that causes acquired immunodeficiency syndrome (AIDS) • World Health Organization (WHO) estimates (end 2012):  34 million people living with HIV in the world  1.2 million in US (Joint United Nations Program on HIV/AIDS)  More than 220000 people (15-49 years) in Mexico (CENSIDA)  26 million are eligible for antiretroviral therapy  9.7 million people had access to antiretroviral therapy 2
  • HIV testing • Many HIV-positive people are unaware that they are infected with the virus. • Less than 1% of the urban population of Africa had been tested for HIV • Plasma testing by ELISA and Western Blot are used to detect antibodies to HIV-1, which are accurate but also complex and expensive. Needles, samples need storage equipment and a suitable environment, transportation*, centrifuge, ELISA kit, spectrophotometer, people, lab, permits, etc 3
  • Practical HIV test • High Sensitivity and Specificity (high degree of confidence) • No False Positive or Negatives • Point-of-care test • Non-invasive • Convenient and Inexpensive • Positive results always require a confirmatory test, regardless of the mean of testing 4
  • Available tests • Tests may detect antibodies, antigens, or RNA from serum, urine or oral mucosal transudate samples • The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test detects antibodies to HIV-1/2 (OraSure Technologies, Inc) • Approved for oral fluid, plasma, fingerstick or venipuncture whole blood specimens. • Greater than 99% agreement with confirmatory Western blot. 5
  • OraQuick ADVANCE® disadvantages • Needs oral mucosal transudate samples (not saliva) • Chances of contamination (many steps) • Saturation threshold at 400 mIU • 20 to 40 minute period for results • This product does not have approval for marketing and selling in Mexico 6
  • QikTech One-Step HIV I/II/O Saliva Test 7
  • Government Permits • Obtaining all documentation and permits Mexican Department of Health and COFEPRIS (equivalent to US FDA) • Registration (Class II) • JAJ International representative (POA) • Permit of importation of product 8
  • 9
  • 10 PAYMENT METHOD: APPLICATION FOR AUTHORIZATION OF PROTOCOL RESEARCH INVOLVING HUMAN.
  • Medical Centers and Organizations • Hospital General de Tijuana (500 register patient) • Prevencasa A.C (aprox. 400 subjects get tested per month) • CENSIDA/CAPASITS (1700 register patient) 11
  • 12
  • 13
  • 14
  • Tentative Protocol • Inclusion criteria males and females ages 18 to 64 Participating medical center and organization personal and/or MEDEVISE personal trained to: - To give and obtain inform consent from patient - Guide patient with the correct use of the tests - Collect samples and record results - Provide guidance for further testing and for medical/psychological support 15
  • Tentative Protocol • Collection of samples and data would take place at:  The moment a subject get tested (in site testing)  Inviting register patients to participate in the study • Register patients can be invited to participate in the study:  At the moment of visit to physician for regular checks  At the moment of visit to hospital for medication  Can be invited to participate in the study by phone call (gift cards incentives) 16
  • Tentative Protocol • QikTech One-Step HIV I/II/O Saliva Test results can be compered to: Neogen HIV-1/2 and syphilis (Treponema pallidum) test (INTERBIOL S.A. de C.V.); blood sample by fingerstick (In site testing) Samples that test positive can be further analyzed with ELISA and/or Western Blots and results are going to compared again to QikTech results 17
  • Test comparison • Goal: to collect 250 or more samples of test that indicate positive and 250 or more samples of test that specify negative of QikTech for comparison of diagnosis accuracy to those of Neogen kit. • Proper Statistical analysis would be performed on the data and a final report of results and conclusions would be provided to JAJ International 18
  • Conclusion • If QikTech One-Step HIV I/II/O Saliva Test results are comparable and accurate to those of Neogen HIV-1/2 and syphilis blood test then we can: Submit manuscript for publication Submit application for commercialization of QikTech One-Step HIV I/II/O Saliva Test in Mexico 19
  • Conclusion • If product is approved for commercialization in Mexico: It would provide a rapid, flexible, simple and accurate method for the detection of HIV, overcoming the disadvantage and limitations of current products in the market Mexico can be a platform to sell the product to in other countries Promote early detection of HIV and early treatment can be provided to patient, thus improving quality of life 20
  • 21 RESOURCE / SERVICE COST DESCRIPTION STUDY DESIGN 2500 ONCE: PATIENT SELECTION, PROTOCOL MODEL, FORMATS, CONSULTATIONS HOSPITAL FEE 2500 ONCE: REVIEW BY AUTHORIZED BIOETHIC COMISSION (COFEPRIS) PRINCIPAL INVESTIGATOR 1000 MONTHLY OCTAVIO ROMO FEWELL RESEARCH COORDINATOR 1000 MONTHLY MARCO VELAZCO RIVERA REGISTRATION 1500 ONCE: APPLICATION, IMPORT PERMIT, WITHOUT TRAVEL EXPENSES OUTSOURCING 1500 CONTRIBUTIONS FOR CLINICIANS, LETTERS, DOCUMENTATION, INFORMATIVE MATERIALS, PATIENT INCENTIVES, TRANSLATIONS, BEFORE ALL OPEX MUST BE SUMMARIZED/COMMERCIAL INVOICES 20000 6 MONTHS OF CLINICAL TRIAL + MONTHLY REPORTS, OUTCOMES ANALYSES 40 DAYS SANITARY REG. ROI GH GENERAL HOSPITAL1000 UNITS MONTHLY ONE G.H. 3.5 per unit $ 3,500 23 MONTHS 32 GENERAL HOSPITALS + OTC 8000 UNITS MONTHLY 16 GH (500) MONTH 3.5 per unit $ 28,000 16,000 UNITS MONTHLY 16 (1K) MONTH $ 56,000 PATIENTS BETWEEN 15 a 49 YRS OLD LIVING WITH HIV 220K PREVALENCE 0.3% IN MEXICO ( 1 FOR EACH 1000) C o n c e n t r a t e d E p i d e m i c CensidaCensida (2010a). «Estadísticas». Panorama epidemiológico del VIH/sida e ITS en México. Ciudad de México: Censida. CensidaCensida (2010b). «Casos nuevos y acumulados de sida en jóvenes (15-29 años), por categoría de transmisión y sexo» (en español, PDF). Panorama epidemiológico del VIH/sida e ITS en México. Ciudad de México: Censida.
  • References • http://www.who.int/hiv (World Health Organization) • Kumaranayake L, Watts C (2001). "Resource allocation and priority setting of HIV/AIDS interventions: addressing the generalized epidemic in sub-Saharan Africa". Journal of International Development 13 (4): 451–466. doi:10.1002/jid.797 • http://www.unaids.org/en/ (Joint United Nations Programme on HIV/AIDS) • http://www.cdc.gov/hiv (Centers for Disease Control and Prevention ) • Pant Pai N, Balram B, Shivkumar S, Martinez-Cajas JL, Claessens C, Lambert G, Peeling RW, Joseph L (2012) Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. The Lancet. DOI:10.1016/S1473- 3099(11)70368-1 • Leea SR, Yearwooda GD, Guillona GB, Kurtza LA, Fischla M, Frielb T, Bernec CA, Kardosa KW (2010) Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. Journal of Clinical Virology. doi:10.1016/j.jcv.2010.02.018 22
  • THANK YOU & TAKE A LOOK OF THE SAMPLE PRODUCT… 23
  • 24
  • 25